Last reviewed · How we verify
Regenexx SD® procedure
Regenexx SD uses autologous bone marrow-derived stem cells to promote tissue regeneration and reduce inflammation in degenerative joint conditions.
Regenexx SD uses autologous bone marrow-derived stem cells to promote tissue regeneration and reduce inflammation in degenerative joint conditions. Used for Osteoarthritis of the knee, Osteoarthritis of the hip, Osteoarthritis of the shoulder.
At a glance
| Generic name | Regenexx SD® procedure |
|---|---|
| Sponsor | Regenexx, LLC |
| Drug class | Autologous stem cell therapy |
| Modality | Biologic |
| Therapeutic area | Orthopedics / Regenerative Medicine |
| Phase | Phase 3 |
Mechanism of action
The procedure involves harvesting bone marrow from the patient, concentrating stem cells and growth factors, and injecting them directly into damaged joints. These stem cells are believed to differentiate into cartilage-forming cells, reduce inflammatory cytokines, and stimulate the body's natural healing response to repair degenerative tissue.
Approved indications
- Osteoarthritis of the knee
- Osteoarthritis of the hip
- Osteoarthritis of the shoulder
- Degenerative disc disease of the spine
Common side effects
- Injection site pain or swelling
- Temporary increase in joint pain
- Infection at injection site
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |